Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
While no oncologist can be an expert in every type of cancer, GRACE does not aim to replace your doctors. Our faculty are specialists in their fields, focusing on specific types of cancer. GRACE connects experts with patients and families, fostering a community where information is shared, and everyone can learn from one another. We provide balanced, evidence-based cancer information from a core group of experts, accessible in various formats to cater to different needs.
In the GRACE forums, you can ask questions or share comments, which will be addressed by our skilled moderators and experts. This opens up opportunities for informative discussions with others who may have similar concerns or insights. Through communication and collaboration, we believe some of the most valuable information emerges. All content on cancerGRACE.org is free, accessible, and searchable, so you can find the information you need at any time. GRACE offers a supportive community for heartfelt discussions, virtual hugs, and connections whenever you need them.
This live virtual event, led by Dr. Andrew Srisuwananukorn on October 25, 2025, brought together top oncologists to share the latest updates in blood cancer treatment. The program featured patient-focused presentations, expert panel discussions, and a real-time Q&A session where attendees could engage directly with specialists. To watch the complete playlist, click here.
The Problem Many cancer patients and their families don't have access to reliable information because of health inequity The Solution Your support for GRACE allows us to empower patients through free, credible, cancer treatment education Support GRACE in our only fundraiser! We rely on you to be able to continue providing the most current and emerging research and educational information to those who need it most Your DONATION helps us to continue helping others! Because of you, GRACE has...
In this video series led by Dr. Siddharth Sheth and recorded on October 27, 2025, a panel of leading oncologists engages in a dynamic and insightful roundtable discussion as they share newly released data, key highlights, and significant developments in head and neck cancer treatment while addressing the most pressing questions, delivered in a concise and easy-to-understand format. To watch the complete playlist, click here.
In this series, the 2024-25 Clinical Trials Experiences Through Storytelling Program, we talk to cancer survivors who have a passion for telling their stories in order to help others who may be navigating the clinical trials experience. In this 2nd series of videos, Michael Herman takes us through the story of his diagnosis, his struggles with treatment options, his clinical trial and his learning curve. Thank you to our Sponsors! #lilly #exelixis To join the conversation or ask a question...
In this series, Vernon Sondak, Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and Fiorinda Muhaj, MD Anderson Cancer Center, discuss basal and squamous cell carcinoma, including diagnosis, treatment options, and skin cancer prevention. To watch the complete playlist, click here. Thanks to Regeneron and Daiichi-Sankyo.
En esta serie de videos, los oncólogos, Luis Raez, MD FASCO FACP; Estelamari Rodríguez, MD, MPH; Miguel González Velez, MD y Suraj Samtani, MD, presentan la información de tratamiento más actual y emergente sobre el cáncer de pulmón a pacientes y cuidadores en un formato de video conciso y fácil de entender. Mira la serie completa aquí.
Liquid biopsies are revolutionizing how doctors detect and treat cancer. Unlike traditional tissue biopsies, which require removing a piece of the tumor, liquid biopsies use a simple blood test to reveal vital genetic information about a patient’s cancer—often faster and with fewer complications. While still used mainly in advanced lung cancer, liquid biopsies are poised to become a frontline tool across many cancer types in the coming years—offering a faster, less invasive path to precision care.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: